摘要
非酒精性脂肪性肝病(NAFLD)患者中有一部分可发展为非酒精性脂肪性肝炎(NASH),当NASH的纤维化程度F≥2且NAFLD活动度评分≥4时,该阶段的NASH被称为纤维化NASH,是药物临床试验中的重点关注对象。目前肝组织活检是评估肝组织学变化的金标准,但因其有创性限制了临床上的应用,因此开发纤维化NASH的非侵入性检测方法显得尤为重要。本文总结了近年来针对纤维化NASH的新型无创诊断方法的相关研究成果,阐述了新型诊断方法对纤维化NASH预测的现状、面临的挑战和未来的发展前景。
A subset of patients with non-alcoholic fatty liver disease(NAFLD)can progress to nonalcoholic steatohepatitis(NASH).When NASH reaches a fibrosis degree of F≥2 and a NAS score of≥4,this stage of NASH is referred to as fibrotic NASH,which is a key focus in clinical drug trials.Currently,liver biopsy is the gold standard for assessing the histological changes of the liver,but its clinical application is limited by its invasiveness,and therefore,it is of particular importance to develop noninvasive detection methods for fibrotic NASH.This article summarizes the recent research achievements in novel noninvasive diagnostic methods for fibrotic NASH and elaborates on these new diagnostic methods for predicting fibrotic NASH in terms of current status,challenges faced,and prospects for future development.
作者
冯巩
孔荣耀
王嘉学
吴天悦
武晓慧
王菊宁
严琴琴
弥曼
FENG Gong;KONG Rongyao;WANG Jiaxue;WU Tianyue;WU Xiaohui;WANG Juning;YAN Qinqin;MI Man(Institute of General Practice,Xi’an Medical University,Xi’an 710021,China;School of Clinical Medicine,Xi’an Medical University,Xi’an 710021,China;School of General Practice,Xi’an Medical University,Xi’an 710021,China;Department of Infectious Diseases,The First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China;School of Medicine,Xi’an Peihua University,Xi’an 710199,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2024年第11期2293-2299,共7页
Journal of Clinical Hepatology
基金
陕西省教育厅项目(23JK0646)
陕西省自然科学基础研究计划(2023-JC-YB-699)
西安医学院科研能力提升计划项目(2022NLTS098)
西安市科协青年人才托举计划(959202413081)。
关键词
非酒精性脂肪性肝病
纤维化
生物标记
诊断
人工智能
Non-alcoholic Fatty Liver Disease
Fibrosis
Biomarkers
Diagnosis
Artificial Intelligence